Insights & Resources – COD Research – Designing Therapies For Future

The Evolution of PRO Collection: From Paper Diaries to ePRO Systems

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Biometrics

Clinical Services

CT Quality Assurance

Medical Affairs

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

Strategic Planning for Patient Recruitment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Zentiva, emtricitabine,tenofovir disoproxil, Date of authorisation: 09/11/2016, Revision: 11, Status: Authorised
Source: EMA Published on 2026-09-02
Human medicines European public assessment report (EPAR): Rebif, interferon beta-1a, Date of authorisation: 03/05/1998, Revision: 43, Status: Authorised
Source: EMA Published on 2026-09-02
Human medicines European public assessment report (EPAR): Cinacalcet Accordpharma, cinacalcet, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised
Source: EMA Published on 2026-09-02
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes
Source: EMA Published on 2026-09-02
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
Source: EMA Published on 2026-09-02
Pre-submission interactions form for marketing authorisation application
Source: EMA Published on 2026-09-02

Read More